
Pluripotent stem cells are entering early phase 1 and 2 clinical trials for a range of applications, including the treatment of macular degeneration and other eye diseases, spinal cord injury, heart disease, type 1 diabetes, and Parkinson's disease. By necessity, both pluripotent embryonic stem…
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2woq4JG
http://ift.tt/2fbyBMG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου